* Bionano Genomics Inc BNGO.OQ reported a quarterly
adjusted
loss of 51 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of $-1.20. The mean expectation of four analysts
for the quarter was for a loss of 64 cents per share. Wall
Street expected results to range from -72 cents to -57 cents per
share.
* Revenue rose 18.3% to $8.77 million from a year ago;
analysts
expected $8.49 million.
* Bionano Genomics Inc's reported EPS for the quarter was a
loss
of 60 cents.
* The company reported a quarterly loss of $31.42 million.
* Bionano Genomics Inc shares had fallen by 17.1% this
quarter and
lost 51.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 14.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Bionano Genomics
Inc is $6.00
This summary was machine generated from LSEG data May 9 at 06:26
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.64 -0.51 Beat
Dec. 31 2023 -0.87
Sep. 30 2023 -0.97 -1.00 Missed
Jun. 30 2023 -1.03 -1.24 Missed